Stock News

EPS for Corvus Pharmaceuticals, Inc. (CRVS) Expected At $-0.66; Oncosec Medical (ONCS) Sellers Increased By 1.83% Their Shorts

Oncosec Medical (NASDAQ:ONCS) had an increase of 1.83% in short interest. ONCS’s SI was 1.84M shares in February as released by FINRA. Its up 1.83% from 1.81M shares previously. With 1.09M avg volume, 2 days are for Oncosec Medical (NASDAQ:ONCS)’s short sellers to cover ONCS’s short positions. The SI to Oncosec Medical’s float is 9.73%. It closed at $1.64 lastly. It is down 34.57% since February 10, 2017 and is downtrending. It has underperformed by 51.27% the S&P500.

Analysts expect Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) to report $-0.66 EPS on March, 9.They anticipate $0.11 EPS change or 20.00% from last quarter’s $-0.55 EPS. After having $-0.62 EPS previously, Corvus Pharmaceuticals, Inc.’s analysts see 6.45% EPS growth. The stock decreased 2.93% or $0.24 during the last trading session, reaching $7.95. About 163,837 shares traded or 75.82% up from the average. Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has declined 11.61% since February 10, 2017 and is downtrending. It has underperformed by 28.31% the S&P500.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. The company has market cap of $167.28 million. The Company’s lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. It currently has negative earnings. The firm is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase.

Among 4 analysts covering OncoSec Medical (NASDAQ:ONCS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. OncoSec Medical had 10 analyst reports since March 9, 2016 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, July 21 by Rodman & Renshaw. H.C. Wainwright maintained the shares of ONCS in report on Friday, June 2 with “Buy” rating. The stock of OncoSec Medical Incorporated (NASDAQ:ONCS) earned “Buy” rating by Maxim Group on Thursday, June 8. The company was maintained on Friday, December 15 by H.C. Wainwright. The firm has “Buy” rating by Noble Financial given on Tuesday, June 13. On Thursday, November 9 the stock rating was maintained by H.C. Wainwright with “Buy”. Maxim Group maintained the stock with “Buy” rating in Friday, June 2 report. H.C. Wainwright maintained the stock with “Buy” rating in Monday, June 12 report. The stock has “Buy” rating by H.C. Wainwright on Friday, January 19. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, March 9 report.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. The company has market cap of $70.42 million. The Company’s lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. It currently has negative earnings. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *